PT-141 in Canada: A Research Guide to Its Receptor Profile

For labs buying PT-141 in Canada, the compound is usually a tool for studying melanocortin receptors in cell-based systems. Getting useful data from it depends on three things that have little to do with the label: knowing what its receptor profile actually is, choosing an assay that matches how those receptors signal, and keeping the material consistent across the many vials a screening campaign consumes. This guide covers each, along with the structural feature that makes PT-141 easier to handle than many cyclic peptides: its lactam bridge.

PT-141 in Canada: what research groups use it for

PT-141, also known by its nonproprietary name bremelanotide, is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. In the research setting it is used mainly in receptor pharmacology: binding studies, second-messenger assays and comparisons with related ligands in cells that express one or more melanocortin receptor subtypes. Its key identity figures are a formula of C50H68N14O10 and an average molecular weight near 1025.2 g/mol.

From alpha-MSH to a seven-residue ring

The melanocortin agonists used in research all trace back to alpha-melanocyte-stimulating hormone, a thirteen-residue linear peptide. Medicinal chemists found that a short core of that sequence, His-Phe-Arg-Trp, carries most of the receptor activity, and that locking the core into a ring strengthens binding. Melanotan 2 was one result: a seven-residue cyclic analog with norleucine at the start, a D-phenylalanine in the core and a C-terminal amide. PT-141 is the same ring with a free carboxylic acid at the C-terminus instead of the amide.

That relationship means PT-141 and Melanotan 2 sit close together in mass and on a chromatogram. The identity side of that problem is covered in our Melanotan 1, Melanotan 2 and PT-141 comparison. This article concentrates on pharmacology and practical assay work.

The receptor profile, stated carefully

Five melanocortin receptors are known, MC1R through MC5R. MC2R is the ACTH receptor and does not respond meaningfully to alpha-MSH analogs of this kind. The other four do, to different degrees.

PT-141 is described in the pharmacology literature as an agonist at several of these subtypes, including MC1R, MC3R, MC4R and MC5R, with the bulk of published attention on MC4R and MC3R. Reported potency values for each subtype vary between studies, cell backgrounds and readouts. Two practical conclusions follow:

• Treat PT-141 as a multi-subtype agonist unless your own data in your own system show otherwise.
• Always run a reference agonist, such as alpha-MSH or the potent analog NDP-alpha-MSH, alongside it in the same plate, so relative potency is measured rather than borrowed from a paper.

Where a design needs to separate MC3R and MC4R contributions from the rest, published antagonists such as SHU9119 and the endogenous antagonist agouti-related protein are the usual tools. Our overview of melanocortin receptor subtypes sets out the family in more depth.

Designing an in-vitro assay around a Gs-coupled receptor

All four responsive subtypes belong to class A of the GPCR superfamily and signal mainly through the Gs protein. Activation stimulates adenylyl cyclase and raises intracellular cAMP. That makes cAMP accumulation, or a cAMP-responsive reporter, the natural readout.

A few design points save time:

1. Match the readout to the coupling. A calcium flux assay suits Gq-coupled receptors, such as the kisspeptin receptor described in kisspeptin-10 and KISS1R signalling, but it can miss a perfectly active melanocortin agonist.
2. Use single-subtype cell lines for selectivity questions. Many cell types express more than one melanocortin receptor, so a response in a native line is a composite.
3. Include a phosphodiesterase inhibitor where the assay method calls for it, so cAMP accumulates enough to measure.
4. Watch the low end of the concentration range. Peptides at nanomolar concentrations can stick to plastic, which flattens the bottom of a concentration-response curve. Low-binding plates and a carrier protein in the buffer help.

Why a lactam ring is easier to work with than a disulfide

Many cyclic peptides are closed by a disulfide bond between two cysteines. PT-141 is closed instead by a lactam: an amide bond between the side chains of aspartic acid and lysine. For assay work this has clear advantages.

• A lactam is not opened by reducing agents such as dithiothreitol or beta-mercaptoethanol, so buffers containing them are not a threat to the ring.
• There is no free thiol to take part in exchange reactions with other thiol-containing components.
• The ring cannot scramble into the wrong connectivity, a problem that can affect peptides with several disulfides.

The analytical check that matters is whether the ring closed during synthesis. The open, linear precursor weighs about 18 Da more than the cyclic product, because forming the amide bond releases water, and it runs at a different retention time. A certificate reporting both the calculated and the measured mass lets you rule it out. The general chemistry is covered in cyclic versus linear peptides.

Running a campaign across many vials

Receptor screening can consume a surprising number of vials, and the biggest threat to comparable data is switching lots halfway through. Practical steps for a larger order:

• Size the order to cover the whole campaign from one lot where possible.
• When a new lot must be introduced, run it side by side with the old one on the same plate before retiring the old lot, and record the comparison.
• Calculate molar concentrations from net peptide content rather than label weight, since counter-ions and water are part of the powder. The net peptide content guide explains the difference.
• Prepare concentrated analytical stocks once and divide them into single-use portions, rather than thawing and refreezing one stock repeatedly.

Our article on lot-to-lot variation and trending goes further into tracking consistency over time.

Receiving and recording PT-141

Many labs that hold PT-141 also hold Melanotan 2, and the two lyophilised powders look identical. Store them in separate, clearly labelled containers, match each vial’s cap and crimp colour to its certificate, and log compound, lot and vial count at receipt. Our guide to inventory labels and records suggests a workable format.

We stock PT-141 10mg vials alongside the rest of our melanocortin peptides, shipped from within Canada with mix-and-match volume pricing. Products are third-party tested for purity by HPLC, and certificates are published for some products on our certificates of analysis page.

PT-141 is sold by Bulk Peptides for in-vitro laboratory research only. It is not for human or veterinary use, and this article describes receptor-level research, not any use in people.